Skip to main content
GutCited

L-Glutamine Crohn's Disease

C

Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

結論

Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.

Key Study Findings

Other
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Dose: None vs: None Outcome: Gut microbiota composition 効果: None None

対象集団: Crohn's disease patients

Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None vs: None Outcome: Cholesterol levels 効果: None None

対象集団: Mouse model

Controlled Clinical Trial
Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study.
Dose: Washed microbiota transplantation (WMT) vs: Pre-treatment baseline Outcome: Clinical remission and multi-omics changes 効果: None None

対象集団: Patients with Crohn's disease

In Vitro
Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production.
Dose: Beclin1 constitutive activation (genetic) vs: Wild-type mice Outcome: Cytokine production in macrophage activation 効果: None None

対象集団: Beclin1 variant mice + AIEC infection

Observational Study n=262
Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn's Disease and Exacerbates Colitis in …
Dose: Phenylacetylglutamine (PAGln, measured) vs: Healthy controls (n=126) Outcome: PAGln association with CD and colitis 効果: None None

対象集団: New-onset treatment-naive CD (n=136) + controls

Observational Study
COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Dose: None vs: None Outcome: CAM use patterns in IBD patients 効果: None None

対象集団: Brazilian IBD patients

Key Statistics

3

研究数

200

参加者数

Positive

C

グレード

Referenced Papers

Sheng wu gong … 2022 4 件の引用
The Cochrane database … 2018 425 件の引用
Gastroenterology clinics of … 2018 67 件の引用
Current opinion in … 2017 37 件の引用
The Cochrane database … 2016 37 件の引用
Inflammatory bowel diseases 2010 89 件の引用
Molecular nutrition & … 2008 26 件の引用
The Cochrane database … 2007 192 件の引用
Current opinion in … 2005 22 件の引用
Clinical nutrition (Edinburgh, … 2004 18 件の引用
Medycyna wieku rozwojowego 2004 1 件の引用
Alimentary pharmacology & … 2003 179 件の引用
Revista do Hospital … 2002 39 件の引用
Current opinion in … 2002 1 件の引用
Current opinion in … 2002
The Cochrane database … 2001 149 件の引用
Current opinion in … 2000 21 件の引用
Diseases of the … 1998 26 件の引用
Zeitschrift fur Gastroenterologie 1998 18 件の引用
Schweizerische medizinische Wochenschrift. … 1996

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
5-15 g/day
ibsdsupport:
5 g three times daily (15 g/day total)
postexercisegut:
0.25-0.9 g/kg before intense exercise
gutbarriersupport:
0.5 g/kg/day (approximately 30-40 g/day for adults)

上限量: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day

研究で検討された用量

用量 期間 効果 N
None -- Positive --
None -- Positive --
Washed microbiota transplantation (WMT) -- Positive --
Beclin1 constitutive activation (genetic) -- Positive --
Phenylacetylglutamine (PAGln, measured) -- Negative 262
None -- Mixed --
None -- Negative --
None -- Mixed --

推奨摂取タイミング: Between meals or before exercise; divide doses throughout the day

Safety & Side Effects

報告されている副作用

  • Mild gastrointestinal discomfort at high doses
  • Headache
  • Dizziness at very high doses
  • Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)

既知の相互作用

  • Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
  • Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
  • Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)

耐容上限摂取量: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does L-Glutamine help with Crohn's Disease?
Based on 3 studies with 200 participants, there is limited but promising evidence that L-Glutamine may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。